Literature DB >> 19116094

Integration of surgery and systemic therapy in the management of metastatic renal cancer.

Anil A Thomas1, Brian I Rini, Steven C Campbell.   

Abstract

Integration of surgery and systemic therapies represents the best management option for most patients with metastatic renal cell carcinoma. Cytoreductive nephrectomy, metastasectomy, and consolidative surgery can all play a vital role in this challenging patient population. Relevant issues in this era relate to the timing of surgery, the role of cytoreduction as systemic therapies become more effective, management of the residual mass, and surgical safety after targeted therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19116094     DOI: 10.1007/s11934-009-0008-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  42 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

5.  Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis.

Authors:  H G van der Poel; J A Roukema; S Horenblas; A N van Geel; F M Debruyne
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

6.  Hepatic resection for metastatic renal tumors: is it worthwhile?

Authors:  A Alves; R Adam; P Majno; V Delvart; D Azoulay; D Castaing; H Bismuth
Journal:  Ann Surg Oncol       Date:  2003-07       Impact factor: 5.344

7.  Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review.

Authors:  P C Kierney; J A van Heerden; J W Segura; A L Weaver
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

8.  Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Authors:  Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell
Journal:  J Urol       Date:  2008-12-18       Impact factor: 7.450

9.  Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Authors:  Wassim Kassouf; Ricardo Sanchez-Ortiz; Pheroze Tamboli; Nizar Tannir; Eric Jonasch; Madhur M Merchant; Surena Matin; David A Swanson; Christopher G Wood
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

10.  Surgery for solitary metastases of the spine: rationale and results of treatment.

Authors:  Narayan Sundaresan; Allen Rothman; Karen Manhart; Kevin Kelliher
Journal:  Spine (Phila Pa 1976)       Date:  2002-08-15       Impact factor: 3.468

View more
  3 in total

1.  [Aggressive fibromatosis (desmoid tumor) : A rare differential diagnosis of metastasis of renal cell carcinoma].

Authors:  A Janitzky; M Porsch; M Daher; D Küster; U-B Liehr
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 2.  Heterogeneity and renal mass biopsy: a review of its role and reliability.

Authors:  Jeffrey J Tomaszewski; Robert G Uzzo; Marc C Smaldone
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

Review 3.  Cytoreductive surgery in the era of targeted molecular therapy.

Authors:  Arun Z Thomas; Mehrad Adibi; Leonardo D Borregales; Jose A Karam; Christopher G Wood
Journal:  Transl Androl Urol       Date:  2015-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.